Tracer library / [67Cu]Cu-SARTATE
[67Cu]Cu-SARTATE
Also written as [Cu-67]Cu-SARTATE; SarTATE
- Radionuclide
- Cu-67 t½ 3708 min
- Modality
- Therapy
- Production route
- —
- Stage
- Preclinical
- Syntheses indexed
- 0
What it is
- Compound class
- CB-TE1A1P-PEG4-LLP2A (VLA-4-targeting peptidomimetic conjugated to CB-TE1A1P chelator)
- Target / mechanism
- VLA-4 (integrin α4β1) PMID 39911068
- Clinical application
- Neuroendocrine tumors (preclinical); unresectable multifocal meningioma (clinical) PMID 32414949
- Theranostic pair
- [64Cu]Cu-sartate
Published syntheses
No synthesis has been parsed for this agent yet.
Clinical literature
Clinical studies in the indexed corpus, ordered by design (multicentre, prospective, retrospective, others, case reports last) and then by year. Titles and links only, as published; this is not a summary of the evidence.
Need this precursor?We can point you to suppliers for [67Cu]Cu-SARTATE, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 1 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Diagnostic pair signal at discovery: YES - Cu-64. Compound class inferred from precursor name (not stated outright) -- PMID 39911068: 'CB-TE1A1P-PEG4-LLP2A (LLP2A) was kindly provided by AusPep (34).'. Stage set/updated at stage 23 from PMID 39911068: 'We used orthotopic syngeneic (i.e., B16-F10, B78, 4T1, GL261, TH-MYCN, and E2A-PBX1) and human (i.e., SK-MEL-37, 143B, and IMR-5) cancer models for in vivo PET/CT imaging and biodistribution studies.'.